[羟羧氧酰胺菌素对医院细菌的体外作用。一项多中心调查结果]
[In vitro action of moxalactam on hospital bacteria. Results of a multicenter survey].
作者信息
Duval J, Deforges L, Bergogne-Berezin E, Chabbert Y A, Courtieu A L, Cluzel R, Dabernat H, Witchitz J L
出版信息
Sem Hop. 1983 Jun 30;59(26):1949-52.
The high potency of Moxalactam on three major groups of bacteria, i.e. Enterobacteriae, Haemophilus and Bacteroïdes, predicted by previous studies, has been confirmed by the study of hospital strains in this multicenter investigation. Among these groups, the proportion of resistant strains is very low. However, Moxalactam is not superior to older agents on staphylococci, Streptococci and Listeria, and is less active than certain new agents on Pseudomonas. Moxalactam is one of the best "third generation" cephalosporins. It is remarkable by its potency against Bacteroides fragilis and its weak activity on Streptococci and Pneumococci. The unanswered question concerns the future of resistant strains: will they remain exceptional or will they multiply?
先前研究预测的羟羧氧酰胺菌素对三大类细菌（即肠杆菌科细菌、嗜血杆菌属和拟杆菌属）的高效能，已在这项多中心调查中对医院菌株的研究得到证实。在这些菌群中，耐药菌株的比例非常低。然而，羟羧氧酰胺菌素在葡萄球菌、链球菌和李斯特菌方面并不优于旧的药物，在假单胞菌方面其活性低于某些新药。羟羧氧酰胺菌素是最好的“第三代”头孢菌素之一。它对脆弱拟杆菌的效能显著，而对链球菌和肺炎球菌的活性较弱。尚未解决的问题涉及耐药菌株的未来：它们会仍然罕见还是会增多？
Zotero 插件